Volume 2, Issue 1, January 2016, Page: 7-12
Biomodulators of Anxiety
Preetham Elumalai, School of Aquatic Food Products and Technology, Kerala University of Fisheries and Ocean Studies, Panangad, Kochi, Kerala, India
Sreeja Lakshmi, School of Aquatic Food Products and Technology, Kerala University of Fisheries and Ocean Studies, Panangad, Kochi, Kerala, India
Received: Dec. 17, 2015;       Accepted: Jan. 7, 2016;       Published: Feb. 19, 2016
DOI: 10.11648/j.ijcems.20160201.12      View  4260      Downloads  67
Abstract
Anxiety is a feeling of unease which everyone feels at some points in their lives. Anxiety becomes a disorder when the symptoms become chronic and interfere daily lives, including behavioral patterns and adaptations. Anxiety disorders come in many forms - Generalized Anxiety Disorder, Panic and Post-traumatic Stress disorders, Obsessive Compulsive Disorders, Social Anxiety Disorders and various Phobias. The state of anxiety is modulated by a multifarious and complex series of biomodulators of the categories, neurotransmitters, peptides and hormones comprising serotonin, norepinephrine, Gamma-Aminobutyric acid (GABA), cortisol, Corticotropin Releasing Factor (CRF), Acetylcholine and many more. The article reviews the anxiogenic and/or anxiolytic functions of selected biomodulators in maintaining anxiety related behaviours.
Keywords
Anxiety, GABA, Serotonin, Norepinephrine, HPA Axis
To cite this article
Preetham Elumalai, Sreeja Lakshmi, Biomodulators of Anxiety, International Journal of Clinical and Experimental Medical Sciences. Vol. 2, No. 1, 2016, pp. 7-12. doi: 10.11648/j.ijcems.20160201.12
Copyright
Copyright © 2016 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Ninan P T. Dissolving the burden of generalized anxiety disorder. J Clin Psychiatry. 2001; 62.
[2]
Higgins E S and Gorge M S. The neuroscience of clinical psychiatry: The pathophysiology behaviour and mental illness. 1st edition. 2007.
[3]
Rachman S. Clinical Psychology: Anxiety. 1998.
[4]
Etkin A. Functional neuroanatomy of anxiety: a neural circuit perspective. Curr Top Behav Neurosci. 2010; 251-277.
[5]
Kessler R C, McGonagle K A, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 8-19.
[6]
Gilhotra N and Dhingra D. Neurochemical modulation of anxiety disorders. International Journal of Pharmacy and Pharmaceutical Sciences. 2010; 1-6.
[7]
Ishikawa R, Kobori O and Shimizu E. Development and validation of the Japanese version of the obsessive-compulsive inventory. BMC Res Notes. 2014; 306.
[8]
Fricchione G. Generalized anxiety Disorder. N Engl J Med. 2004; 675-682.
[9]
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (Fifth edition). Washington, D.C.: American Psychiatric Association; 2013.
[10]
Creighton A S, Davison T E and Kissane D W. The prevalence of anxiety among older adults in nursing homes and other aged care facilities: a systematic review. Int J Geriatr Psychiatry. 2015; doi: 10.1002/gps.4378.
[11]
Kang H J, Yoon S and Lyoo I K. Peripheral Biomarker candidates of posttraumatic stress disorder. Exp Neurobiol. 2015; 186-196.
[12]
Schneier F R. Social Anxiety Disorder. N Engl J Med. 2006; 1029-1036.
[13]
Bourne and Edmund J. The anxiety and phobia workbook (5th ed.) New harbinger Publications. 2011; 50-51.
[14]
Young E A, Abelson J L and Cameron O G. Effect of co-morbid anxiety disorders on the hypothalamic-pituitary-adrenal axis response to a social stressor in major depression. Biol Psychiatry. 2004; 113-120.
[15]
Rose L E, McLean L M. Anxiety disorders during pregnancy and the postpartum period. J Clin Psychiatry. 2006; 1285-1298.
[16]
Gladstone G L, Parker G B, Malhi G S. Do bullied children become anxious and depressed adults?: A cross-sectional investigation of the correlates of bullying and anxious depression. J Nerv Ment Dis. 2006; 201-208.
[17]
Gamez W, Watson D, Doebbeling B N. Abnormality personality and the mood and anxiety disorders: Implications for structural models of anxiety and depression. J Anxiety Disord. 2007; 526-539.
[18]
Karatzias A. Chouliara Z, Power K and Swanson V. Predicting general well-being from self-esteem and affectivity: An extrapolatory study with Scottish adolescents. Qual Life Res. 2006; 1143-1151.
[19]
Steimer T. The biology of fear and anxiety-related behaviours. Dialogues Clin neurosci. 2002; 231-249.
[20]
Deepak M, Alok T S, Paresh W J, Abhijit S V and Anil CV. Neurobilogical modulators of anxiety. International Research Journal of Pharmacy. 2012; 60-64.
[21]
Bannerman DM, Rawlins JN, McHugh SB, et al. Regional dissociations within the hippocampus – memory and anxiety. Neurosci Biobehav Rev. 2004; 273–283.
[22]
Tanaka M, Yoshida M, Emoto H, Ishii H. Noradrenaline systems in the hypothalamus, amygdala and locus coeruleus are involved in the provo- cation of anxiety: basic studies. Eur J Pharmacol. 2000; 397-406.
[23]
Geracioti T D. CSF norepinephrine concentrations in post-traumatic stress disorder. Am J Psychiatry. 2001; 1227-1230.
[24]
Kao C Y, Stalla G, Stalla J, Wotjak CT, Anderzhanova E. Norepinephrine and corticosterone in the medial prefrontal cortex and hippocampus predict PTSD/like symptoms in mice. Eur J Neurosci. 2015; 1139-1148.
[25]
Lin S H, Lee L T and Yang Y K. Serotonin and mental disorders: a concise review on molecular neuroimaging evidence. Clin Psychopharmacol Neurosci. 2014; 196-202.
[26]
Marchesi C, Ossola P, Amerio A, Daniel B D, Tonna M, De Panfilis C. Clinical management of perinatal anxiety disorders: A systematic review. J Affect Disord. 2015; 543-550.
[27]
Lanzenberger RR, Mitterhauser M, Spindelegger C, et al. Reduced serotonin-1A receptor binding in social anxiety disorder. Biol Psychiatry. 2007; 1081-1089.
[28]
Van der Wee N J, van Veen J F, Stevens H, van Vliet I M, van Rijk p P and Westenberg H G. Increased serotonin and dopamine transporter binding in psychotropic medication naive patients with generalized social anxiety disorder shown by 123I-beta-(4-iodophenyl)-tropane SPECT. J Nucl Med. 2008; 757-763.
[29]
Nuss P. Anxiety disorders and GABA neurotransmission: a disturbance of modulation. Neuropsychiatr Dis Treat. 2015; 165-175.
[30]
Mantella RC, Butters MA, Amico JA, et al. Salivary cortisol is associated with diagnosis and severity of late-life generalized anxiety disorder. Psychoneuroendocrinology. 2008; 773–781.
[31]
Lenze EJ, Mantella RC, Shi P, et al. Elevated cortisol in older adults with Generalized Anxiety Disorder is reduced by treatment: a placebo-controlled evaluation of escitalopram. Am J Geriatr Psychiatry. 2011; 482-490.
[32]
Magin G N, Heinrichs S C and Dunn A J. The role of CRH in behavioral responses to stress. Peptides. 2001; 713-724.
[33]
Victoria B R and Murray B S. Role of Corticotropin Releasing Factor in anxiety disorders: A translational research perspective. Horm Behav. 2006; 550-561.
[34]
Kutlu M G and Gould T J. N. Nicotine modulation of fear memories and anxiety: Implications for learning and anxiety disorders. Biochem Pharmacol. 2015; 498-511.
[35]
Tresa M M, Natalie E P, Sharon R G, Stephen E H and Booker T K. 42 Nicotinic acetylcholine receptors on dopaminergic neurones mediate nicotine reward and anxiety relief. J. Neurosci. 2011; 10891-10902.
[36]
Koopmann A, Lemenager T, Wolf N D, et al. The impact of atrial natriuretic peptide on anxiety, stress and craving in patients with alcohol dependence. Alcohol and Alcoholism. 2013; 282-286.
[37]
Rotzinger S and Vaccarino F J. Cholecystokinin receptor subtypes:role in the modulation of anxiety-related and reward-related behaviours in animal models. J Psychiatry Neurosci. 2003; 171-181.
[38]
Moreira F A and Wotlak C T. Cannabinoids and anxiety. Curr Top Behav Neurosci. 2010; 429-450.
[39]
Silk D B, Davis A, Vulevic J, Tzortzis G and Gibson G R. Clinical trial: The effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther. 2009; 508-518.
[40]
Bravo J A, Forsythe P, Chew M V, et al. Ingestion of Lactobacillus strain regulates emotional bahaviour and central GABA receptor expression in an mouse via the vagus nerve. Proc Natl Acad Sci USA. 2011; 16050-16055.
[41]
Bercik P, Park AJ, Sinclair D, et al. The anxiolytic effect of Bifidobacterium longum NCC 3001 involves vagal pathways for gut-brain communcation. Neurogastroenetrl Motil. 2011; 1132-1139.
[42]
Desbonnet L, Garrett L, Clarke G, Kiely B, Cryan J F and Dinan T G. Effets of the probiotic Bifidobacterium infantis in the maternal seperation model of depression. Neuroscience. 2010; 1179-1188.
[43]
Buydens-Branchey L and Branchey M. n-3 polyunsaturated fatty acids decrease anxiety feelings in a population of substance abusers. J Clin Psychopharmacol. 2006; 661-665.
[44]
de Sousa DP, Hocayen Pde A, Andrade LN, Andreatini R. A systematic review of the anxiolytic- like effects of essential oils in animal models. Molecules. 2015; 18620-18660.
[45]
Yoga for the Treatment of Post-Traumatic Stress Disorder, Generalized Anxiety Disorder, Depression, and Substance Abuse: A Review of the Clinical Effectiveness and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Jun. CADTH Rapid Response Reports. Available from: http://www.ncbi.nlm.nih.gov/books/NBK304569/
Browse journals by subject